`
`
`
`v.
`
`NOVO NORDISK INC. and NOVO
`NORDISK A/S,
`
`
`
`
`
`VIATRIS INC. and
`MYLAN PHARMACEUTICALS INC.,
`
`
`
`
`
`
`
`C.A. No. 1:23-cv-13
`
`
`
`
`
`Case 1:23-cv-00013-TSK Document 36 Filed 06/14/23 Page 1 of 3 PageID #: 421
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`
`
`
`
`
`
`
` Defendant.
`
`
`JOINT MOTION FOR EXTENSION
`
`Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S, and Defendants Viatris Inc. and
`
`Mylan Pharmaceuticals Inc., by their undersigned counsel, hereby move the Court for an extension
`
`of the deadline to submit the Joint Report of Initial Planning Meeting that is currently due June 14,
`
`2023 under the Court’s Order Extending Deadlines dated May 18, 2023 (Dkt. No. 32).
`
`While the parties appreciate that the Court previously denied a request for an extension of
`
`time (Dkt. 34), the parties have since appeared for a scheduling conference in the Delaware
`
`Wegovy Action, captioned Novo Nordisk Inc. and Novo Nordisk A/S v. Viatris Inc. and Mylan
`
`Pharmaceuticals Inc., 1:23-cv-00101-CFC (D. Del.). The Delaware court ordered trial to proceed
`
`in the Delaware Wegovy Action in December 2024, and Defendants have represented that they
`
`intend to proceed in the Delaware Wegovy Action. A final schedule for the Delaware Wegovy
`
`Action is due to be submitted to the Delaware court on June 20, 2023. The parties are currently
`
`negotiating the dates for the final schedule in the Delaware Wegovy Action in view of the
`
`Delaware court’s guidance at the Delaware Wegovy Action scheduling conference. Following
`
`entry of a final schedule in the Delaware Wegovy Action, the parties expect this West Virginia
`
`
`
`
`
`
`
`Case 1:23-cv-00013-TSK Document 36 Filed 06/14/23 Page 2 of 3 PageID #: 422
`
`Wegovy Action to be dismissed, avoiding the need for the Court to consider a schedule in this
`
`case.
`
`Accordingly, to avoid burdening the Court and to avoid conflicting dates between the
`
`Delaware Wegovy Action and the West Virginia Wegovy Action, and in view the anticipated
`
`dismissal of this West Virginia Wegovy Action, the parties respectfully request that the date for
`
`submission of a Joint Report of Initial Planning Meeting that is currently due June 14, 2023 under
`
`the Court’s Order Extending Deadlines dated May 18, 2023 (Dkt. No. 32) be extended to June 28,
`
`2023.
`
`
`
`
`
`
`
`2
`
`
`
`
`
`Case 1:23-cv-00013-TSK Document 36 Filed 06/14/23 Page 3 of 3 PageID #: 423
`
`
`
`
`
`PERKINS COIE LLP
`
`
`/s/ Brandon M. White
`Brandon M. White (WV Bar No. 14021)
`BMWhite@perkinscoie.com
`PERKINS COIE LLP
`700 13th Street, NW, Suite 800
`Washington, DC 20005
`(202) 654-6200
`bmwhite@perkincoie.com
`
`Attorney for Defendants, Viatris Inc. and Mylan
`Pharmaceuticals Inc.
`
`
`
`
`Dated: June 14, 2023
`
`Respectfully submitted,
`
`SCHRADER COMPANION DUFF & LAW,
`PLLC
`
`/s/ James F. Companion
`James F. Companion (#790)
`Sandra K. Law (#6071)
`401 Main Street
`Wheeling, WV 26003
`(304) 233-3390
`jfc@schraderlaw.com
`skl@schraderlaw.com
`
`
`Attorneys for Plaintiffs, Novo Nordisk Inc
`and Novo Nordisk A/S
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`